Use of PRO Onc Assay to Assess HER2 in Patients With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
This trial will evaluate the clinical significance of the PRO Onc assay and will assess the
efficacy of HER2-targeted therapy in patients with HER2-negative breast cancer who have been
identified as having HER2 overexpression/activation by the PRO Onc Assay.